I. MODIFIED AGREEMENTS

Company* (Country; Symbol)

Company* (Country; Symbol)

Change from original agreement

Terms/Details (Date)


Actelion Ltd. (Switzerland; SWX:ATLN)

Celltech Group plc (UK; NYSE:CLL)

Modified deal covering Zavesca, which is approved for Type I Gaucher's disease

Actelion has full rights and responsibilities for the drug in glycolipid disorders; Celltech previously could have re-acquired rights; Celltech manufactures the product and gets royalties on sales (6/16)

Array BioPharma Inc. (ARRY)

Trimeris Inc. (TRMS)

They renewed 2001 deal for the discovery of small- olecule entry inhibitors for HIV

Array is entitled to research funding as well as potential milestones and royalties; terms are similar to those in the original deal (6/3)

Biolex Inc.*

Centocor Inc. (unit of Johnson & Johnson)

Expanded deal to include limited scale-up of the first of three Centocor proteins expressed in Biolex's LEX System

Centocor also added a fourth protein to the deal, terms of which were not disclosed (6/4)

Cepheid Inc. (CPHD)

Applied Biosystems Group (NYSE:ABI) and Celera Diagnostics (venture of ABG and Celera Genomics Group; NYSE:CRA)

Nonexclusive license deal on real-time thermal cycler instruments for research, diagnostic and other uses

Expanded deal adding diagnostics to Cepheid's rights to use thermal cyclers under Applera's patent rights; hepatitis C and HIV are not included in the deal (6/23)

OSI Pharmacueticals Inc. (OSIP)

Genentech Inc. (NYSE:DNA)

Amended January 2001 deal to further clarify roles for development and sales of the cancer drug Tarceva in the U.S.

OSI will provide at least 25% of the sales force; they will share post-launch development responsibilities; OSI is responsible for the NDA filing and is responsible for manufacturing for the U.S. market (6/16)

Nanobac Life Sciences Inc. (OTC BB:NNBP)

Pegasus Worldwide Inc.*

Nanobac exercised its right to take over marketing of its nanobiotic regimen

Details were not disclosed; nanobacteria are associated with pathologic calcification in various diseases (6/18)

II. TERMINATED AGREEMENTS

Amrad Corp. (Australia; ASX:AML)

Serono SA (Switzerland; NYSE:SRA)

Serono returned rights to emfilermin, a product for increasing pregnancy rates, after a failed trial

Amrad does not expect to further develop the leukemia inhibitory factor compound as an infertility treatment (6/2)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SWX = Swiss Stock Exchange.

No Comments